Imigran Juvenil (Sumatriptan)

Sumatriptan works by selectively stimulating 5‑HT1B and 5‑HT1D receptors located on cranial blood vessels and trigeminal nerve endings. This action causes vasoconstriction of dilated intracranial vessels and blocks the release of inflammatory neuropeptides, interrupting the migraine pain pathway.

The dose of Imigran Juvenil is individualized by the prescribing clinician based on the patient’s age, severity of migraine, and prior response to therapy. The prescriber determines the number of sprays and the interval between doses, following the product’s labeling and clinical guidelines.

Safety data for sumatriptan in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any potential risk to the fetus or infant. Healthcare providers will assess the individual situation before prescribing.

To order Imigran Juvenil, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imigran Juvenil delivers sumatriptan via a nasal spray, offering a non‑oral route that can act faster than many oral triptans, especially when nausea limits tablet absorption. Compared with other triptans such as rizatriptan tablets, the nasal formulation may provide quicker onset but shares similar efficacy and safety profiles.

Imigran Juvenil should be stored at room temperature, below 25 °C, in its original packaging. Protect the spray from moisture, excessive heat and direct sunlight. Do not freeze the product, and keep the nozzle clean to maintain proper dosing.

The medication is administered as a nasal spray. The patient tilts the head slightly forward, inserts the nozzle into one nostril, and actuates the device to deliver the prescribed number of sprays. The dose may be repeated after a specified interval if needed, according to the prescriber’s instructions.

Serious risks include chest pain or tightness, which may indicate cardiac ischemia, and serotonin syndrome, a potentially life‑threatening condition when combined with other serotonergic drugs. Severe allergic reactions such as anaphylaxis can also occur. Patients should seek immediate medical attention if any of these symptoms appear.

Imigran Juvenil is contraindicated in patients with known coronary artery disease, uncontrolled hypertension, a history of stroke or transient ischemic attack, and in those who have taken MAO inhibitors within the past 14 days. It should also be avoided in patients with severe hepatic impairment or known hypersensitivity to sumatriptan.